

# Yun Ling

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4449394/publications.pdf>

Version: 2024-02-01

44  
papers

5,655  
citations

331538

21  
h-index

254106

43  
g-index

49  
all docs

49  
docs citations

49  
times ranked

14370  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 91.	7.1	14
2	Integrated analysis of gut microbiome and host immune responses in COVID-19. <i>Frontiers of Medicine</i> , 2022, 16, 263-275.	1.5	35
3	An open, prospective cohort study of WJ16 in Chinese participants infected with SARS-CoV-2 omicron variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 1518-1523.	3.0	42
4	Shufeng Jiedu, a promising herbal therapy for moderate COVID-19: Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study. <i>Phytomedicine</i> , 2021, 85, 153390.	2.3	60
5	Co-infection in COVID-19, a cohort study. <i>Journal of Infection</i> , 2021, 82, 414-451.	1.7	11
6	An inter-correlated cytokine network identified at the center of cytokine storm predicted COVID-19 prognosis. <i>Cytokine</i> , 2021, 138, 155365.	1.4	30
7	Correlation Between Early Plasma Interleukin 37 Responses With Low Inflammatory Cytokine Levels and Benign Clinical Outcomes in Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 223, 568-580.	1.9	17
8	Dynamic anti-spike protein antibody profiles in COVID-19 patients. <i>International Journal of Infectious Diseases</i> , 2021, 103, 540-548.	1.5	25
9	A streamlined clinical metagenomic sequencing protocol for rapid pathogen identification. <i>Scientific Reports</i> , 2021, 11, 4405.	1.6	15
10	Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 287-298.	1.6	5
11	Epigenetic Landscapes of Single-Cell Chromatin Accessibility and Transcriptomic Immune Profiles of T Cells in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 625881.	2.2	30
12	Vitamin C supplementation is necessary for patients with coronavirus disease: An ultra-high-performance liquid chromatography-tandem mass spectrometry finding. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 196, 113927.	1.4	23
13	Immune profiles of a COVID-19 adolescent with mild symptoms and anti-viral antibody deficiency. <i>Fundamental Research</i> , 2021, 1, 117-123.	1.6	2
14	Case report: histopathology and molecular pathology analysis on enteric tissue of a COVID-19 patient. <i>Diagnostic Pathology</i> , 2021, 16, 40.	0.9	3
15	Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19. <i>Cell Discovery</i> , 2021, 7, 42.	3.1	23
16	Analysis of risk factors of PICC-related bloodstream infection in newborns: implications for nursing care. <i>European Journal of Medical Research</i> , 2021, 26, 80.	0.9	10
17	Dynamics of TCR repertoire and T cell function in COVID-19 convalescent individuals. <i>Cell Discovery</i> , 2021, 7, 89.	3.1	27
18	Pre-optimized phage therapy on secondary <i>Acinetobacter baumannii</i> infection in four critical COVID-19 patients. <i>Emerging Microbes and Infections</i> , 2021, 10, 612-618.	3.0	80

#	ARTICLE	IF	CITATIONS
19	Risk factors for myocardial injury at admission of 325 patients with coronavirus disease 2019 in Shanghai, China. <i>Australasian Journal on Ageing</i> , 2021, , .	0.4	3
20	ç³ç±³â”æµ«â°æšæœ`âœ`é†ç–†æ–°â†è,°ç,žæ,£è€...ç»šâæ,,ÿæÿ“è-šæ-ä,çš,,â”ç””. <i>Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Science</i> , 2020, 51(1), 10-14.		
21	Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population. <i>Emerging Microbes and Infections</i> , 2020, 9, 1988-1996.	3.0	58
22	Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection. <i>Frontiers of Medicine</i> , 2020, 14, 746-751.	1.5	57
23	Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa241.	0.4	97
24	Preliminary investigation of relationship between clinical indicators and CT manifestation patterns of COVID-19 pneumonia improvement. <i>Journal of Thoracic Disease</i> , 2020, 12, 5896-5905.	0.6	0
25	The Course of Mild and Moderate COVID-19 Infectionsâ€”The Unexpected Long-Lasting Challenge. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa286.	0.4	19
26	A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-Î² plus TFF2 in patients with moderate COVID-19. <i>EClinicalMedicine</i> , 2020, 25, 100478.	3.2	20
27	Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. <i>JAMA Internal Medicine</i> , 2020, 180, 1356.	2.6	211
28	Blood molecular markers associated with COVID-19 immunopathology and multi-organ damage. <i>EMBO Journal</i> , 2020, 39, e105896.	3.5	123
29	Clinical Potential of <sup>1</sup> H-MRI for Assessing COVID-19: Patient- and Lesion-Based Comparative Analysis. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 397-406.	1.9	48
30	Epidemiology and clinical course of COVID-19 in Shanghai, China. <i>Emerging Microbes and Infections</i> , 2020, 9, 1537-1545.	3.0	24
31	Clinical progression of patients with COVID-19 in Shanghai, China. <i>Journal of Infection</i> , 2020, 80, e1-e6.	1.7	627
32	Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. <i>Chinese Medical Journal</i> , 2020, 133, 1039-1043.	0.9	686
33	Viral and host factors related to the clinical outcome of COVID-19. <i>Nature</i> , 2020, 583, 437-440.	13.7	746
34	Application of ordinal logistic regression analysis to identify the determinants of illness severity of COVID-19 in China. <i>Epidemiology and Infection</i> , 2020, 148, e146.	1.0	20
35	Observations about symptomatic and asymptomatic infections of 494 patients with COVID-19 in Shanghai, China. <i>American Journal of Infection Control</i> , 2020, 48, 1045-1050.	1.1	28
36	Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia. <i>Radiology</i> , 2020, 295, 210-217.	3.6	997

#	ARTICLE	IF	CITATIONS
37	COVID-19 with Different Severities: A Multicenter Study of Clinical Features. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1380-1388.	2.5	690
38	A simple algorithm helps early identification of SARS-CoV-2 infection patients with severe progression tendency. Infection, 2020, 48, 577-584.	2.3	25
39	Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19. BioScience Trends, 2020, 14, 161-167.	1.1	8
40	Switch of NAD Salvage to de novo Biosynthesis Sustains SIRT1-RelB-Dependent Inflammatory Tolerance. Frontiers in Immunology, 2019, 10, 2358.	2.2	25
41	Genetic and Clinical Profiles of Disseminated Bacillus Calmette-Guérin Disease and Chronic Granulomatous Disease in China. Frontiers in Immunology, 2019, 10, 73.	2.2	10
42	Mitochondrial Sirtuin 4 Resolves Immune Tolerance in Monocytes by Rebalancing Glycolysis and Glucose Oxidation Homeostasis. Frontiers in Immunology, 2018, 9, 419.	2.2	69
43	Clinical Immunophenotype at Disease Onset in Previously Healthy Patients With Cryptococcal Meningitis. Medicine (United States), 2016, 95, e2744.	0.4	1
44	Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. Journal of Experimental Medicine, 2015, 212, 619-631.	4.2	162